The final, formatted version of the article will be published soon.
CASE REPORT article
Front. Med.
Sec. Dermatology
Volume 12 - 2025 |
doi: 10.3389/fmed.2025.1485079
Dupilumab for treatment of primary cutaneous amyloidosis in adults: Two case reports and literature review
Provisionally accepted- 1 Huzhou Central Hospital, Huzhou, China
- 2 Zhejiang University, Hangzhou, China
Lichenoid amyloidosis (LA), a subtype of primary cutaneous amyloidosis (PCA), is featured by intensely pruritic, hyperkeratotic papules which lacks standardized treatment. Dupilumab, a human monoclonal antibody targeting for interleukin (IL)-4/13 receptor α chain, is widely applied in type 2 inflammation diseases treatment. This article reported two cases of refractory LA successfully treated with dupilumab and reviewed publications reporting dupilumab treatment for PCA.
Keywords: dupliumab, Amyloidosis, Amyloidosis - therapy, case report, review
Received: 06 Nov 2024; Accepted: 14 Jan 2025.
Copyright: © 2025 Guo, Zhong, Wu, Xu, Tan, Zhou and Tang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Qiang Zhou, Zhejiang University, Hangzhou, China
Shunli Tang, Zhejiang University, Hangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.